Electrophysiology

The cardiac subspecialty of electrophysiology (EP) diagnoses and treats arrhythmias. This includes use of pacemakers to treat bradycardia, implantable cardioverter defibrillators (ICD) for tachycardia, heart failure and patients at risk of sudden cardiac arrest, and cardiac ablation treatments to treat heart rhythm disorders.

RSS icon

Heart Rhythm Society launches new group focused on EP advocacy

The new organization, Heart Rhythm Advocates, will urge federal policymakers to pass legislation and support actions that have a positive impact on the future of electrophysiology.

Medtronic's Affera mapping and ablation system with the Sphere-9 catheter

FDA approves Medtronic’s new all-in-one mapping and ablation system for AFib

Medtronic is now the first company to offer two FDA-approved PFA systems for the treatment of persistent AFib. The company’s PulseSelect PFA system gained approval in December 2023. 

Boston Scientific has received U.S. Food and Drug Administration (FDA) approval for its Farawave Nav ablation catheter for the treatment of paroxysmal atrial fibrillation (AFib) and FDA clearance for its new Faraview software

Boston Scientific scores 2 key FDA approvals for PFA mapping technology

The two newly approved technologies are used together to help visualize cardiac ablation procedures performed with Boston Scientific’s Farapulse pulsed field ablation system.

cardiologist salary and compensation data

Cardiologist compensation still rising, especially in invasive and interventional cardiology

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Overview of the pathophysiological mechanisms associated with arrhythmogenesis in the setting of COVID-19 infection. Image from Circulation.

AHA issues a scientific statement on COVID-19 cardiac arrhythmias

The objective of the AHA scientific statement is to review the available evidence on for better management of cardiac arrhythmias from COVID causes that are still encountered on a regular basis.

Cardiologists have performed what they believe to be the world’s first substernal lead extraction, sharing their experience in JACC: Case Reports.[1]The device being extracted, Medtronic’s Aurora EV-ICD, received U.S. Food and Drug Administration (FDA) approval in October 2023.

Cardiologists perform world’s first substernal lead extraction

The 49-year-old patient was not in pain or suffering any complications, but he wished to have his extravascular ICD removed once his symptoms improved. The care team agreed to extract it after a long discussion, and they said it was "easier than expected." 

The OmniaSecure defibrillation lead, which Medtronic describes as “the world's smallest transvenous defibrillation lead,” has a size of just 4.7 French.

Medtronic’s OmniaSecure, the smallest ICD lead of its kind, linked to long-term durability

Reliability modeling suggests the small-diameter defibrillation lead, already linked to positive early outcomes, should last patients for at least 10 years—and likely longer. 

cardiologists evaluating the human heart to provide a treatment strategy

Rising heart failure, AFib rates a ‘wake-up call’ for US cardiologists

Today's heart teams already face a number of challenges on a day-to-day basis.  New data suggest they could soon be treating more patients than ever before.  

Displaying 41 - 48 of 399

Around the web

Radiology Business
The impact of Trump tariffs on iodine contrast media costs

GE HealthCare said the price of iodine contrast increased by more than 200% between 2017 to 2023. Will new Chinese tariffs drive costs even higher?

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.